Epic Sciences receives CAP accreditation.
Epic Sciences announced today that they have received notice of their accreditation from the College of American Pathologists (CAP) for its San Diego laboratory.
Circulating tumor cells linked with treatment resistance and response in prostate cancer patients.
Research teams at Memorial Sloan Kettering Cancer Center and Epic Sciences have found that greater diversity among circulating tumor cells (CTCs) in the blood of advanced prostate cancer patients predicts not only shorter overall survival, but also the development of resistance to key anti-androgen therapies.
Epic Sciences enters into 35th pharma collaboration to advance companion diagnostics for new targeted therapeutics.
Epic Sciences, a private biotech company that develops novel diagnostics to personalize and advance the treatment and management of cancer, announced today that it has signed its 35th collaboration agreement with pharmaceutical companies.
Epic Sciences' chief scientific officer named leading global thinker by Foreign Policy magazine.
Epic Sciences' Chief Scientific Officer Dena Marrinucci, Ph.D., was named today by Foreign Policy magazine as one of this year’s 100 Leading Global Thinkers. Marrinucci will be honored at a gala in Washington, D.C. this evening.
Epic Sciences partners with University of Pennsylvania's Abramson Cancer Center on cancer therapy discoveries through liquid biopsy.
Epic Sciences, Inc. announced today a collaboration with the Abramson Cancer Center of the University of Pennsylvania (Penn) on multiple studies to explore biomarkers, identified by analysis of circulating tumor cells (CTCs) at a single cell resolution, that are predictive of response to personalized cancer therapeutics.
Circulating tumor cells (CTC) in patients' blood detected by Epic Sciences are an "accurate representation" of genetic aberrations found in fresh metastatic tumor samples.
Most men with advanced prostate cancer, whether initially treated through surgical or chemical castration, eventually develop drug-resistant tumors. Monitoring for drug resistant genetic mutations could inform selection of the next line of therapy. A new non-invasive approach developed by Epic Sciences may be as effective at biomarker characterization as invasive surgical biopsies for metastatic castration-resistant prostate cancer (mCRPC) patients.
Epic Sciences' platform capable of single cell CTC identification sequencing in late stage, metastatic cancer.
After successive cancer therapies, multiple subpopulations of cancer cells arise, each with divergent genetic aberrations that may confer drug resistance or susceptibility. Tissue biopsies may not detect these subpopulations, but a liquid biopsy of blood using Epic Sciences’ no cell left behind® technology may help identify these important tumor cells and characterize how a patient’s tumors have evolved over time.